192 related articles for article (PubMed ID: 2478015)
41. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation.
Menzin J; Richner R; Huse D; Colditz GA; Oster G
Ann Pharmacother; 1994 Feb; 28(2):271-5. PubMed ID: 8173149
[TBL] [Abstract][Full Text] [Related]
42. Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent.
Ofosu FA; Levine M; Craven S; Dewar L; Shafai S; Blajchman MA
Br J Haematol; 1992 Oct; 82(2):400-5. PubMed ID: 1329920
[TBL] [Abstract][Full Text] [Related]
43. Deep vein thrombosis prophylaxis in the outpatient setting: preventing complications following hospital discharge.
Turpie AG
Orthopedics; 1995 Jul; 18 Suppl():15-7. PubMed ID: 7479420
[TBL] [Abstract][Full Text] [Related]
44. The pathogenesis and prevention of thromboembolic complications in patients undergoing total hip replacement.
Potyk DK; Tabbarah HJ
J Gen Intern Med; 1993 Apr; 8(4):213-9. PubMed ID: 7685817
[TBL] [Abstract][Full Text] [Related]
45. Intraoperative heparin thromboembolic prophylaxis in primary total hip arthroplasty. A prospective, randomized, controlled, clinical trial.
Huo MH; Salvati EA; Sharrock NE; Brien WW; Sculco TP; Pellicci PM; Mineo R; Go G
Clin Orthop Relat Res; 1992 Jan; (274):35-46. PubMed ID: 1729021
[TBL] [Abstract][Full Text] [Related]
46. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
47. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement.
Eriksson BI; Zachrisson BE; Teger-Nilsson AC; Risberg B
Br J Surg; 1988 Nov; 75(11):1053-7. PubMed ID: 2463035
[TBL] [Abstract][Full Text] [Related]
48. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
Colwell CW; Spiro TE; Trowbridge AA; Morris BA; Kwaan HC; Blaha JD; Comerota AJ; Skoutakis VA
J Bone Joint Surg Am; 1994 Jan; 76(1):3-14. PubMed ID: 8288662
[TBL] [Abstract][Full Text] [Related]
49. [Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II].
Ganzer D; Gutezeit A; Mayer G; Greinacher A; Eichler P
Z Orthop Ihre Grenzgeb; 1997; 135(6):543-9. PubMed ID: 9499523
[TBL] [Abstract][Full Text] [Related]
50. [Perioperative management for transurethral resection of bladder tumor (TUR-Bt) associated with congenital antithrombin III deficiency].
Mizuno J; Kato S; Namai S; Komiya Y; Kuwana Y; Morita S
Masui; 2009 Dec; 58(12):1524-7. PubMed ID: 20055199
[TBL] [Abstract][Full Text] [Related]
51. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.
Colwell CW; Collis DK; Paulson R; McCutchen JW; Bigler GT; Lutz S; Hardwick ME
J Bone Joint Surg Am; 1999 Jul; 81(7):932-40. PubMed ID: 10428124
[TBL] [Abstract][Full Text] [Related]
52. Pre- and postoperative levels of antithrombin III with special reference to thromboembolism after total hip replacement.
Fredin H; Nilsson B; Rosberg B; Tengborn L
Thromb Haemost; 1983 Jun; 49(3):158-61. PubMed ID: 6192514
[TBL] [Abstract][Full Text] [Related]
53. [The effect of antithrombin iii concentrations during cardiopulmonary surgery].
Sonzogni V; Bellavita P; Carrara B; Cossolini M; Ferri F; Fabretti F; Mamprin F; Pelliccioli I
Minerva Anestesiol; 2000; 66(1-2):17-23. PubMed ID: 10736978
[TBL] [Abstract][Full Text] [Related]
54. Treatment of venous thrombosis in antithrombin III deficient patients with concentrates of antithrombin III.
Winter JH; Fenech A; Mackie M; Bennett B; Douglas AS
Clin Lab Haematol; 1982; 4(2):101-8. PubMed ID: 7116792
[TBL] [Abstract][Full Text] [Related]
55. A short course of low-molecular-weight heparin to prevent deep venous thrombosis after elective total hip replacement.
Gallay S; Waddell JP; Cardella P; Morton J
Can J Surg; 1997 Apr; 40(2):119-23. PubMed ID: 9126125
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement.
Sagar S; Nairn D; Stamatakis JD; Maffei FH; Higgins AF; Thomas DP; Kakkar VV
Lancet; 1976 May; 1(7970):1151-4. PubMed ID: 58199
[TBL] [Abstract][Full Text] [Related]
57. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.
Hamulyák K; Lensing AW; van der Meer J; Smid WM; van Ooy A; Hoek JA
Thromb Haemost; 1995 Dec; 74(6):1428-31. PubMed ID: 8772214
[TBL] [Abstract][Full Text] [Related]
58. Preventing DVT following total knee replacement: a review of recent clinical trials.
Fitzgerald RH
Orthopedics; 1995 Jul; 18 Suppl():10-1. PubMed ID: 7479418
[TBL] [Abstract][Full Text] [Related]
59. Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement.
Harris WH; Salzman EW; Athanasoulis C; Waltman AC; Baum S; DeSanctis RW
J Bone Joint Surg Am; 1974 Dec; 56(8):1552-62. PubMed ID: 4434023
[No Abstract] [Full Text] [Related]
60. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery.
Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1997 Feb; 77(2):267-9. PubMed ID: 9157579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
